In this study, we have identified factors (loss of BAX; gain of BCL-XL and/or A1) that confer resistance to the new class of BH3-mimetics targeting MCL-1, drugs which are currently being evaluated in clinical trials for diverse blood cancers. Here, BCL2L1 is linked to hematopoietic and lymphoid system neoplasm.